Literature DB >> 21318894

Use of polyamine derivatives as selective histone deacetylase inhibitors.

Patrick M Woster1.   

Abstract

Histone acetylation and deacetylation, mediated by histone acetyltransferase and the 11 isoforms of histone deacetylase, play an important role in gene expression. Histone deacetylase inhibitors have found utility in the treatment of cancer by promoting the reexpression of aberrantly silenced genes that code for tumor suppressor factors. It is unclear which of the 11 histone deacetylase isoforms are important in human cancer. We have designed a series of polyaminohydroxamic acid (PAHA) and polyaminobenzamide (PABA) histone deacetylase inhibitors that exhibit selectivity among four histone deacetylase isoforms. Although all of the active inhibitors promote reexpression of tumor suppressor factors, they produce variable cellular effects ranging from stimulation of growth to cytostasis and cytotoxicity. This chapter describes the procedures used to quantify the global and isoform-specific inhibition caused by these inhibitors, and techniques used to measure cellular effects such as reexpression of tumor suppressor proteins and hyperacetylation of histones H3 and H4. Procedures are also described to examine the ability of PAHAs and PABAs to utilize the polyamine transport system and to induce overexpression of the early apoptotic factor annexin A1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21318894      PMCID: PMC3925779          DOI: 10.1007/978-1-61779-034-8_31

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  33 in total

Review 1.  The human histone deacetylase family.

Authors:  S G Gray; T J Ekström
Journal:  Exp Cell Res       Date:  2001-01-15       Impact factor: 3.905

Review 2.  Deacetylase enzymes: biological functions and the use of small-molecule inhibitors.

Authors:  Christina M Grozinger; Stuart L Schreiber
Journal:  Chem Biol       Date:  2002-01

Review 3.  DNA methylation, methyltransferases, and cancer.

Authors:  K D Robertson
Journal:  Oncogene       Date:  2001-05-28       Impact factor: 9.867

Review 4.  Translating the histone code.

Authors:  T Jenuwein; C D Allis
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

5.  HDAC6 is a microtubule-associated deacetylase.

Authors:  Charlotte Hubbert; Amaris Guardiola; Rong Shao; Yoshiharu Kawaguchi; Akihiro Ito; Andrew Nixon; Minoru Yoshida; Xiao-Fan Wang; Tso-Pang Yao
Journal:  Nature       Date:  2002-05-23       Impact factor: 49.962

Review 6.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

7.  E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia.

Authors:  P G Corn; B D Smith; E S Ruckdeschel; D Douglas; S B Baylin; J G Herman
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

Review 8.  Histone deacetylase inhibitors as new cancer drugs.

Authors:  P A Marks; V M Richon; R Breslow; R A Rifkind
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

9.  Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion.

Authors:  H E Hohmeier; H Mulder; G Chen; R Henkel-Rieger; M Prentki; C B Newgard
Journal:  Diabetes       Date:  2000-03       Impact factor: 9.461

Review 10.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

Authors:  Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.